In the past week, JAGX stock has gone up by 98.00%, with a monthly gain of 112.67% and a quarterly plunge of -49.20%. The volatility ratio for the week is 27.47%, and the volatility levels for the last 30 days are 17.71% for Jaguar Health Inc The simple moving average for the past 20 days is 94.53% for JAGX’s stock, with a -58.43% simple moving average for the past 200 days.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
The stock has a 36-month beta value of 1.00. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 0.56M, and at present, short sellers hold a 9.51% of that float. On April 28, 2025, the average trading volume of JAGX was 38.44K shares.
JAGX) stock’s latest price update
The stock price of Jaguar Health Inc (NASDAQ: JAGX) has jumped by 35.36 compared to previous close of 8.06. Despite this, the company has seen a gain of 98.00% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-17 that Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management Proof-of-concept data in MVID from this study would provide support for crofelemer’s potential inclusion in the EMA’s PRIME program for novel medicines targeting unmet medical needs and the FDA’s Breakthrough Therapies program SAN FRANCISCO, CA / ACCESS Newswire / April 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar’s novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at 4.14% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.98% of loss for the given period.
Volatility was left at 17.71%, however, over the last 30 days, the volatility rate increased by 27.47%, as shares surge +102.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.29% lower at present.
During the last 5 trading sessions, JAGX rose by +98.00%, which changed the moving average for the period of 200-days by -89.48% in comparison to the 20-day moving average, which settled at $5.61. In addition, Jaguar Health Inc saw -56.79% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.64 for the present operating margin
- 0.78 for the gross margin
The net margin for Jaguar Health Inc stands at -3.29. The total capital return value is set at -0.91. Equity return is now at value -522.60, with -73.89 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -0.8. The debt to equity ratio resting at 5.01. The interest coverage ratio of the stock is -50.46.
Currently, EBITDA for the company is -36.66 million with net debt to EBITDA at -0.77. When we switch over and look at the enterprise to sales, we see a ratio of 3.07. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To sum up, Jaguar Health Inc (JAGX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
